Supernus Pharmaceuticals/$SUPN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
- Ticker
- $SUPN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 778
- Headquarters
- Rockville, United States
- Website
- www.supernus.com
SUPN Metrics
BasicAdvanced
$2.4B
-
-$1.91
0.56
-
Price and volume
Market cap
$2.4B
Beta
0.56
52-week high
$59.68
52-week low
$37.54
Average daily volume
917K
Financial strength
Current ratio
2.083
Quick ratio
1.68
Long term debt to equity
0.029
Total debt to equity
0.029
Interest coverage (TTM)
3.77%
Profitability
EBITDA (TTM)
110.432
Gross margin (TTM)
72.89%
Net profit margin (TTM)
-13.23%
Operating margin (TTM)
0.40%
Effective tax rate (TTM)
11.00%
Revenue per employee (TTM)
$1,070,000
Management effectiveness
Return on assets (TTM)
0.39%
Return on equity (TTM)
-10.49%
Valuation
Price to revenue (TTM)
2.892
Price to book
2.36
Price to tangible book (TTM)
5.5
Price to free cash flow (TTM)
127.853
Free cash flow yield (TTM)
0.78%
Free cash flow per share (TTM)
0.327
Growth
Revenue change (TTM)
24.85%
Earnings per share change (TTM)
-267.36%
3-year revenue growth (CAGR)
9.41%
10-year revenue growth (CAGR)
16.59%
3-year earnings per share growth (CAGR)
36.02%
10-year earnings per share growth (CAGR)
14.82%
What the Analysts think about SUPN
Analyst ratings (Buy, Hold, Sell) for Supernus Pharmaceuticals stock.
Analyst projections of the future price of Supernus Pharmaceuticals stock.
Bulls say / Bears say
Second-quarter revenue rose 32%, while the four growth products grew 52%; Supernus also lifted its 2026 revenue guidance. That points to momentum beyond its older brands. (Supernus Pharmaceuticals)
ONAPGO has seven years of FDA orphan-drug exclusivity, and Supernus has filed for approval of a second supplier. Better supply could support the growth of this newer product, which generated $13.5 million in second-quarter sales. (Supernus Pharmaceuticals, Supernus Pharmaceuticals)
Several established products are shrinking: second-quarter sales of Trokendi XR and Oxtellar XR each fell 25%, while APOKYN sales fell 51%. The APOKYN decline also led to a $54.9 million impairment charge. (Supernus Pharmaceuticals)
Despite higher revenue, adjusted operating earnings fell to $31.2 million from $40.9 million a year earlier, and Supernus reported a $58.4 million net loss. The impairment explains much of the reported loss, but the lower adjusted earnings still point to pressure on profitability. (Supernus Pharmaceuticals)
The Indivior deal brings execution and balance-sheet risks: Supernus warns that integration costs and added debt could weigh on the combined company, while expected synergies may be delayed or not realised. The fixed exchange ratio also leaves the value of the stock consideration exposed to share-price moves before closing. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
SUPN Financial Performance
Revenues and expenses
SUPN Earnings Performance
Company profitability
Upcoming events
No upcoming events
SUPN News
AllArticlesVideos
Supernus Pharmaceuticals Q3 Earnings Call Highlights
MarketBeat3 days ago
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript
Benzinga3 days ago
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Business Wire1 month ago
Funds containing SUPN
AllUSDEURGBP
Fund name | Fund size | $SUPN weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.23% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.23% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.23% |
iShares Ageing Population$AGED | $953M | 0.21% |
iShares Ageing Population£AGES | $953M | 0.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.